Cosmo Pharmaceuticals Enhances Management Team with Newly Appointed Head of Global Business Development
Cosmo Pharmaceuticals has appointed Egle Gedrimaite as the new Head of Global Business Development, effective October 1, 2024. Egle brings 15 years of experience in business development and alliance management across pharmaceutical, medical device, and nutraceutical industries. She will report to Giovanni Di Napoli, CEO of Cosmo.
Egle's expertise includes developing successful business in both B2B and B2C sectors, and driving development projects from inception to completion. She holds a degree in International Communications and Communication Systems from the Università per Stranieri di Perugia.
Giovanni Di Napoli expressed enthusiasm about the appointment, emphasizing Cosmo's focus on innovation, excellence, and growth. He also reflected on his first three months as CEO, highlighting the company's commitment to expanding its global footprint and creating value for shareholders.
Cosmo Pharmaceuticals ha nominato Egle Gedrimaite come nuovo Responsabile dello Sviluppo del Business Globale, con effetto dal 1 ottobre 2024. Egle porta con sé 15 anni di esperienza nello sviluppo del business e nella gestione delle alleanze nei settori farmaceutico, dei dispositivi medici e nutraceutici. Riporterà a Giovanni Di Napoli, CEO di Cosmo.
La competenza di Egle include lo sviluppo di attività di successo sia nei settori B2B che B2C, e la gestione di progetti di sviluppo dalla concezione al completamento. Ha conseguito una laurea in Comunicazioni Internazionali e Sistemi di Comunicazione presso l'Università per Stranieri di Perugia.
Giovanni Di Napoli ha espresso entusiasmo riguardo alla nomina, sottolineando l'attenzione di Cosmo per l'innovazione, l'eccellenza e la crescita. Ha anche riflettuto sui suoi primi tre mesi come CEO, evidenziando l'impegno dell'azienda nell'espandere la sua presenza globale e creare valore per gli azionisti.
Cosmo Pharmaceuticals ha nombrado a Egle Gedrimaite como la nueva Jefa de Desarrollo Comercial Global, con efecto a partir del 1 de octubre de 2024. Egle aporta 15 años de experiencia en desarrollo de negocios y gestión de alianzas en las industrias farmacéutica, de dispositivos médicos y nutracéuticos. Reportará a Giovanni Di Napoli, CEO de Cosmo.
La experiencia de Egle incluye el desarrollo de negocios exitosos en los sectores B2B y B2C, así como llevar a cabo proyectos de desarrollo desde su inicio hasta su finalización. Tiene un título en Comunicaciones Internacionales y Sistemas de Comunicación de la Università per Stranieri di Perugia.
Giovanni Di Napoli expresó su entusiasmo por el nombramiento, enfatizando el enfoque de Cosmo en la innovación, la excelencia y el crecimiento. También reflexionó sobre sus primeros tres meses como CEO, destacando el compromiso de la empresa de expandir su presencia global y crear valor para los accionistas.
Cosmo Pharmaceuticals는 Egle Gedrimaite를 새로운 글로벌 비즈니스 개발 책임자로 임명했습니다. 그 효력은 2024년 10월 1일부터 발효됩니다. Egle은 제약, 의료 기기 및 건강 보조식품 산업에서 15년의 비즈니스 개발 및 제휴 관리 경험을 가지고 있습니다. 그녀는 Giovanni Di Napoli, Cosmo의 CEO에게 보고할 것입니다.
Egle의 전문 분야는 B2B와 B2C 부문 모두에서 성공적인 비즈니스를 개발하고, 프로젝트를 구상에서 완성까지 이끄는 것입니다. 그녀는 페루자 외국어 대학교에서 국제 커뮤니케이션 및 통신 시스템 학위를 취득했습니다.
Giovanni Di Napoli는 이번 임명에 대한 열정을 표현하며 Cosmo의 혁신, 우수성 및 성장에 대한 초점을 강조했습니다. 그는 또한 CEO로서의 첫 3개월에 대해 회상하며, 회사의 글로벌 입지 확장 및 주주 가치를 창출하려는 노력을 강조했습니다.
Cosmo Pharmaceuticals a nommé Egle Gedrimaite comme nouvelle Responsable du Développement Commercial Global, à compter du 1er octobre 2024. Egle possède 15 ans d'expérience en développement commercial et en gestion d'alliances dans les secteurs pharmaceutique, des dispositifs médicaux et des nutraceutiques. Elle reportera à Giovanni Di Napoli, CEO de Cosmo.
Les compétences d'Egle incluent le développement d'activités commerciales réussies tant dans les secteurs B2B que B2C, et la conduite de projets de développement de l'idée à l'achèvement. Elle est titulaire d'un diplôme en Communications Internationales et Systèmes de Communication de l'Università per Stranieri di Perugia.
Giovanni Di Napoli a exprimé son enthousiasme concernant cette nomination, soulignant l'accent mis par Cosmo sur l'innovation, l'excellence et la croissance. Il a également réfléchi à ses trois premiers mois en tant que CEO, mettant en avant l'engagement de l'entreprise à élargir son empreinte mondiale et à créer de la valeur pour les actionnaires.
Cosmo Pharmaceuticals hat Egle Gedrimaite zur neuen Leiterin der globalen Geschäftsentwicklung ernannt, deren Amtszeit am 1. Oktober 2024 beginnt. Egle bringt 15 Jahre Erfahrung in der Geschäftsentwicklung und im Management von Allianzen in den Branchen Pharmazie, Medizintechnik und Nutraceuticals mit. Sie wird an Giovanni Di Napoli, den CEO von Cosmo, berichten.
Egles Fachwissen umfasst die Entwicklung erfolgreicher Geschäfte sowohl im B2B- als auch im B2C-Bereich sowie die Leitung von Entwicklungsprojekten von der Idee bis zur Fertigstellung. Sie hat einen Abschluss in Internationalen Kommunikations- und Kommunikationssystemen von der Università per Stranieri di Perugia.
Giovanni Di Napoli äußerte sich begeistert über die Ernennung und betonte Cosmos Fokus auf Innovation, Exzellenz und Wachstum. Er reflektierte auch über seine ersten drei Monate als CEO und hob das Engagement des Unternehmens hervor, seine globale Präsenz auszuweiten und Mehrwert für die Aktionäre zu schaffen.
- Appointment of experienced Head of Global Business Development
- CEO's positive outlook on company growth and innovation
- Focus on expanding global business operations
- None.
Dublin, Ireland--(Newsfile Corp. - September 23, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is excited to announce the appointment of Ms. Egle Gedrimaite, as the new Head of Global Business Development, effective October 1, 2024. Egle Gedrimaite will report to Giovanni Di Napoli, CEO of Cosmo. With extensive experience in expanding global business operations and driving strategic market growth, Egle is a valuable addition to Cosmo’s management team, as the Company continues its ambitious expansion plans.
Egle brings 15 years of experience as Business Development director and Alliance management in pharmaceutical, medical device and nutraceutical industries. Her expertise ranges from developing successful business both in B2B and B2C sectors, steering the growth of both established and newly developed products. Her cross-functional attitude and experience brings her to drive development projects from inception to completion, working in collaboration with all corporate functions to ensure a successful outcome. She holds a degree in International Communications and Communication Systems in International Relations from the Università per Stranieri di Perugia (Italy) and has previously worked for Sofar and Alfasigma.
Giovanni Di Napoli, CEO of Cosmo, commented: “I would like our shareholders to feel the positive energy and forward momentum at Cosmo. We are not just expanding our business; we are fostering a culture that values innovation and excellence at every level. With leaders like Egle on board, I am excited about the path ahead and our capacity to achieve remarkable growth.”
Egle Gedrimaite also shared her excitement, saying: “Joining Cosmo Pharmaceuticals as Head of Global Business Development at this dynamic stage is an incredible opportunity. I am inspired by Cosmo’s vision and the energy within the team, and I am eager to contribute to our shared goals of global leadership and industry innovation.”
Reflecting on his first three months as CEO, Giovanni continued: “My journey with Cosmo has been incredibly rewarding so far, marked by a strong sense of purpose and a clear vision for the future. We are embracing a mindset of growth, innovation, and the empowerment of top talent across our organization. Egle’s appointment as Head of Global Business Development is a testament to our commitment to these values, and I am confident that her expertise will be pivotal as we expand our global footprint and create lasting value for our shareholders.”
About Cosmo
Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. The current growth drivers, including the state-of-the-art GI Genius™ intelligent endoscopy system that enhances polyp detection rates during colonoscopy and the prescription drug Winlevi® to treat acne are generating substantial revenue streams. The Company’s proprietary MMX® technology enables targeted delivery of active ingredients in the colon and is a cornerstone of its product development. Cosmo also has a robust clinical development pipeline, which includes Breezula® for the treatment of androgenetic alopecia. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company currently has approximately 300 employees, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.
Upcoming Calendar of Events
UBS Global Healthcare Conference, California November 11-14, 2024
Jefferies London Healthcare Conference, London November 19-21, 2024
For further information, please contact
Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
hwinchester@cosmopharma.com
Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.
Attachments
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/224200
FAQ
Who is the new Head of Global Business Development at Cosmo Pharmaceuticals (CMOPF)?
What experience does Egle Gedrimaite bring to Cosmo Pharmaceuticals (CMOPF)?
When will Egle Gedrimaite start her role at Cosmo Pharmaceuticals (CMOPF)?
What is Cosmo Pharmaceuticals' (CMOPF) strategy for growth according to the CEO?
